Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Elisa DeStanchina"'
Autor:
James Russell, Louise Fanchon, Hanan Alwaseem, Henrik Molina, Isabella O’Donoghue, Amber Bahr, Elisa deStanchina, Nagavarakishore Pillarsetty, John L. Humm
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 2, Pp n/a-n/a (2022)
Abstract Previously published digital autoradiography of 3H‐labeled capecitabine reveals a near‐uniform distribution of activity throughout a murine pancreatic model. This is in contrast both to 14C‐labeled gemcitabine, and established expectat
Externí odkaz:
https://doaj.org/article/9a2617618920471fbdb6fb46405f3a90
Autor:
Radha Mukherjee, Kiran Gireesan Vanaja, Malvika Sharma, Yangjingyi Ruan Ruan, Hilla Solomon, Elisa deStanchina, Sarat Chandarlapaty, Neal Rosen
Publikováno v:
Cancer Research. 83:3882-3882
The PI3K pathway is a key regulator of metabolism, cell proliferation and migration and some of its components (e.g. PIK3CA, HER2 and PTEN) are frequently altered in cancer by genetic events that deregulate its output. However, inhibitors of componen
Autor:
Rui Liang, Daisuke Tomita, Yusuke Sasaki, John Ginn, Mayako Michino, David J. Huggins, Leigh Baxt, Stacia Kargman, Maaz Shahid, Kazuyoshi Aso, Mark Duggan, Andrew W. Stamford, Elisa DeStanchina, Nigel Liverton, Peter T. Meinke, Michael A. Foley, Richard E. Phillips
Publikováno v:
ACS Med Chem Lett
[Image: see text] Aberrant gene-silencing through dysregulation of polycomb protein activity has emerged as an important oncogenic mechanism in cancer, implicating polycomb proteins as important therapeutic targets. Recently, an inhibitor targeting E
Autor:
Michael Offin, Jennifer L. Sauter, Jacklyn V. Egger, Elisa deStanchina, John T. Poirier, Marjorie G. Zauderer, Charles Rudin, Triparna Sen
Publikováno v:
Cancer Research. 82:51-51
Background: Despite recent treatment advances, malignant pleural mesothelioma (MPM) is an aggressive, recalcitrant malignancy. Currently, histologic subtype (epithelioid/non-epithelioid/biphasic) is the primary prognostic factor; other potential biom
Autor:
Erik Herz, Andrew Burns, Hooisweng Ow, Michelle S. Bradbury, Jedd D. Wolchok, Srikant K. Iyer, David Schaer, Elisa DeStanchina, Valerie A. Longo, Steven M. Larson, Oula Penate-Medina, Pat Zanzonico, Ulrich Wiesner, Miriam Benezra
Publikováno v:
Journal of Clinical Investigation. 121:2768-2780
Nanoparticle-based materials, such as drug delivery vehicles and diagnostic probes, currently under evaluation in oncology clinical trials are largely not tumor selective. To be clinically successful, the next generation of nanoparticle agents should
Autor:
Kalyani Chadalavada, Neal Rosen, Timour Baslan, Elisa DeStanchina, Gouri Nanjangud, Jorge S. Reis-Filho, Michael F. Berger, Luciano G. Martelotto, Yaohua Xue, Scott W. Lowe, Martha Solomon, Piro Lito, Alberto Vides
Publikováno v:
Molecular Cancer Therapeutics. 17:B015-B015
Tumors evolve as they adapt to environmental cues. The principles governing evolution of tumors under the selective pressure of targeted therapy are not well understood. We aimed to evaluate the evolution of resistance and to identify therapeutic mod
Autor:
José Baselga, Jaclyn F. Hechtman, Andrea Cercek, Michael F. Berger, Neal Rosen, Elisa DeStanchina, Leonard B. Saltz, David M. Hyman, Zhan Yao, Efsevia Vakiani, David B. Solit, Rona Yaeger
Publikováno v:
Molecular Cancer Therapeutics. 14:C174-C174
Background: RAF and EGFR inhibitor combinations have shown promising clinical activity in patients with BRAF V600E colorectal cancer, but resistance invariably develops. Methods: To define mechanisms of resistance to RAF/EGFR inhibition, we analyzed
Autor:
Iris Appelmann, Elisa DeStanchina, Gregory Carbonetti, Chong Chen, Scott W. Lowe, Charles J. Sherr
Publikováno v:
Blood. 122:1265-1265
Aggressive Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) that genetically and phenotypically mimics the human disease can be induced by the introduction of cultured p185 (BCR-ABL)-expressing Arf-null pre/pro-B cells into h
Autor:
Poulikos I. Poulikakos, Elisa DeStanchina, Madhavi Tadi, Maytal Gabay, Wai Wong, Eric W. Joseph, S Chandarlapaty, Piro Lito, Christine A. Pratilas, Neal Rosen
Publikováno v:
Cancer Research. 72:1223-1223
Activation of ERK signaling causes feedback inhibition of receptor tyrosine kinase and RAS signaling by multiple mechanisms and limits the steady-state output of the pathway. The V600E BRAF mutant does not depend on RAS-dependent dimerization and is